Sanofi revenue by segment 2014-2023

In 2023, French pharmaceutical and healthcare company Sanofi generated approximately 38 billion euros through its biopharmaceutical segment. Sanofi’s consumer healthcare segment earned the company about 5.2 billion euros in that year.

Sanofi’s top products

Sanofi develops various pharmaceutical products, including Aubagio, Lovenox, and Dupixent. One of the company’s top products based on revenue is also Lantus. In 2023, this long-acting insulin used to treat diabetes, generated some 1.4 billion euros. Aubagio earned the company roughly one billion euros within the same year.

Top U.S. drugs

Based on sales numbers over the last years, Humira is by far the top prescription drug in the United States. Before 2023, the drug generated around 20 billion U.S. dollars in the United States per year. Among the country’s most prescribed medicines, however, are atorvastatin, lisinopril, and levothyroxine.

Revenue of Sanofi by segment from 2014 to 2023 (in million euros)

Characteristic	Pharmaceuticals*	Vaccines*	Consumer Healthcare**	Animal Health**
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

February 2024

More information

Region

Worldwide

Survey time period

2014 to 2023

Supplementary notes

* From 2023 on called "Biopharma" ("Pharmaceuticals" + "Vaccines").
** During 2016, the Animal Health and the Consumer Healthcare segments were the objects of a swap deal between Sanofi and Boehringer Ingelheim. Since 2016, Animal Health revenues were no longer part of Sanofi's total revenues.

Citation formats